Rituximab-induced Interstitial Pneumonitis in a Young Patient: A Case Report and Review of the Literature
Korean Journal of Hematology
; : 423-427, 2007.
Article
in English
| WPRIM (Western Pacific)
| ID: wpr-720983
Responsible library:
WPRO
ABSTRACT
Side effects of rituximab are mild in most cases, but there have been a few cases of severe pulmonary toxicity reported in elderly patients. Here we report a case of interstitial pneumonitis following rituximab treatment in a young patient. A 35-year-old woman with diffuse large B-cell lymphoma was admitted complaining of dry cough and dyspnea without fever after the 3 treatments with rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy. Her chest CT with high-resolution CT scanning confirmed the presence of bilateral diffuse ground-glass opacities. The analysis of arterial blood gases indicated hypoxemia. The pulmonary function testing showed a restrictive pattern. There were no other findings suggesting an infection. The findings were compatible with a rituximab-induced interstitial pneumonitis. After the patient was treated with prednisolone, the symptoms resolved. Cases with rituximab-induced interstitial pneumonitis develop principally in elderly patients. However, the condition also can occur in young patients.
Full text:
Available
Database:
WPRIM (Western Pacific)
Main subject:
Respiratory Function Tests
/
Vincristine
/
Prednisolone
/
Doxorubicin
/
Tomography, X-Ray Computed
/
Lymphoma, B-Cell
/
Lung Diseases, Interstitial
/
Cough
/
Drug Therapy
/
Dyspnea
Limits:
Adult
/
Aged
/
Female
/
Humans
Language:
English
Journal:
Korean Journal of Hematology
Year:
2007
Document type:
Article